Download Rapidly discover receptors and druggable targets

RECEPTOR / TARGET
DECONVOLUTION
SPOTTING YOUR TARGET.
Rapidly discover
receptors and
druggable targets
Retrogenix discovers specific, biologically-relevant
primary receptors and secondary targets by
screening for interactions against >4,000 human
plasma membrane proteins that are individually
over-expressed in their native context in human
cells. Test molecules are allowed to bind and then
specific interactions with target receptors are
identified and confirmed.
PLASMA
MEMBRANE
TARGET
•Uncover receptors for protein ligands,
peptides and viruses
•Deconvolute targets in phenotypic drug
discovery
Screen antibodies, proteins, viruses
and small molecules
•Identify any off-target liabilities
RECENT SUCCESSES
•Interactions via post-translational modifications –
new cancer targeting strategy identifed2
“In less than two months Retrogenix was
able to identify and confirm the target
specificity of multiple antibodies
(over 70% of antibodies provided).”
•Breakthrough in malaria research –
published in Nature3
Head of Antibody Discovery,
Bayer
•Target deconvolution for novel cancer antibodies –
MedImmune project1
1 Molecular Cancer 14:147; 2015 2 Cancer Cell 28(4):500-514; 2015
3 Nature 498:502-5; 2013
WWW.RETROGENIX.COM
OFF-TARGET
PROFILING
SPOTTING YOUR TARGET.
Antibodies – ADCs –
scFvs – CAR T cells –
therapeutic proteins
Screen for cell surface off-targets to:
• Aid pre-clinical safety assessment
• Explain unexpected PK
• Prioritise promising antibody leads
• Complement tissue cross-reactivity studies
• Support IND regulatory submissions
WHY RETROGENIX?
•Unrivalled success rates
•Versatile – wide range of molecules and detection tags
•Low false positives/negatives
•Rapid results
•Scalable
•Biologically relevant
“… the Retrogenix method is a very promising tool
for our concerted antibody and antigen discovery
platforms.”
Christoph Rader, Associate Professor Cancer Biology,
Scripps Research Institute
Award Winning Innovation
Please contact Dr Jim Freeth on +44(0)7789 650932 or [email protected]